PARP inhibitors in prostate cancer: clinical applications
Molecular Biology Reports · 2024
DOI: 10.1007/s11033-024-10034-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Hamidreza Saeidi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
- Department of Biomedical Engineering, Faculty of Engineering, University of Isfahan, Isfahan, Iran. moh_sarraf@yahoo.com.
Zitieren
APA
Saeidi, H., & Sarafbidabad, M. (2024). PARP inhibitors in prostate cancer: clinical applications. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-10034-5
Vancouver
Saeidi H, Sarafbidabad M. PARP inhibitors in prostate cancer: clinical applications. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-10034-5
BibTeX
@article{Saeidi2024,
author = {Saeidi, Hamidreza and Sarafbidabad, Mohsen},
title = {PARP inhibitors in prostate cancer: clinical applications},
journal = {Molecular Biology Reports},
year = {2024},
doi = {10.1007/s11033-024-10034-5}
}
EUVIMED